by mediaid pharmacy | Jan 24, 2026 | Blogs
Afanix 40 mg (Afatinib) is an advanced targeted cancer therapy widely prescribed for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Manufactured under strict pharmaceutical standards, Afanix Tablet 40 mg belongs to the class of...
by mediaid pharmacy | Jan 24, 2026 | Blogs
Ibrutix 140 mg is a targeted oral cancer medication containing Ibrutinib, widely prescribed for several blood-related malignancies. It belongs to the class of Bruton’s Tyrosine Kinase (BTK) inhibitors, offering precision-based therapy with proven clinical outcomes....
by mediaid pharmacy | Jan 22, 2026 | Blogs
Ponatinix 15 mg (Ponatinib) is a third-generation tyrosine kinase inhibitor (TKI) widely prescribed in oncology for resistant or relapsed chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). What Is Ponatinix 15...
by mediaid pharmacy | Jan 22, 2026 | Blogs
Osimertinib (Tagrix) 40mg & 80mg is a next-generation targeted therapy widely prescribed in oncology for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). As a third-generation EGFR tyrosine kinase inhibitor (TKI), Osimertinib is clinically proven...
by mediaid pharmacy | Jan 21, 2026 | Blogs
Olanib 50 mg is an oral anti-cancer medicine containing Olaparib INN, a PARP inhibitor widely used in targeted oncology therapy. It is prescribed mainly for BRCA-mutated cancers and selected solid tumors under specialist supervision. What Is Olanib Tablet 50mg? Olanib...
